• Climb Bio released initial Phase 1 data for CLYM116, positioning the drug for less frequent dosing in IgA nephropathy.
• The readout showed sustained target suppression with accompanying reductions in disease-related antibodies, supporting a long-acting profile.
• Safety findings were clean in healthy volunteers, with no major tolerability signals flagged in the dataset.
• A Phase 2 IgA nephropathy study is ongoing, with initial results expected in H1 2027; a Phase 3 start is planned for 2027.
• Additional Phase 1 updates, including a separate China healthy-volunteer study, are scheduled for presentation in Q4 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Climb Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609030700PRIMZONEFULLFEED9820641) on September 03, 2026, and is solely responsible for the information contained therein.